Sixteen patients received first-line EGFR-TKIs within 30 days; one died 1 day after the initiation of EGFR-TKIs, and 2 patients were not followed up because they were transferred to another hospital, and the other 13 patients discontinued first-line EGFR-TKIs within 30 days due to adverse events (hepatic dysfunction, N = 5; gastrointestinal toxicity, N = 4; heart failure, N = 1; pancreatitis, N = 1; fever, N = 1; anemia, N = 1). The gene discussed is EGFR; the disease is pancreatitis.